Simplification to abacavir/lamivudine + atazanavir maintains viral suppression and improves bone and renal biomarkers in ASSURE, a randomized, open label, non-inferiority trial

Public Deposited
Analytics

Downloadable Content

Download PDF
Request Version for Screen Reader
Creator
  • Wohl, D.A.
    • Affiliation: School of Medicine, Department of Medicine
  • Bhatti, L.
    • Other Affiliation: AIDS Healthcare Foundation
  • Small, C.B.
    • Other Affiliation: New York Medical College
  • Edelstein, H.
    • Other Affiliation: Alameda County Medical Center
  • Zhao, H.H.
    • Other Affiliation: GlaxoSmithKline
  • Margolis, D.A.
    • Other Affiliation: GlaxoSmithKline
  • DeJesus, E.
    • Other Affiliation: Orlando Immunology Center
  • Weinberg, W.G.
    • Other Affiliation: Kaiser Foundation Health Plan of Georgia, Inc.
  • Ross, L.L.
    • Other Affiliation: ViiV Healthcare
  • Shaefer, M.S.
    • Other Affiliation: ViiV Healthcare
Abstract
  • Objective: Simplification of antiretroviral therapy in patients with suppressed viremia may minimize long-term adverse effects. The study's primary objective was to determine whether abacavir/lamivudine + atazanavir (ABC/3TC +ATV) was virologically non-inferior to tenofovir/emtricitabine + atazanavir/ritonavir (TDF/FTC+ATV/r) over 24 weeks in a population of virologically suppressed, HIV-1 infected patients. Design: This open-label, multicenter, non-inferiority study enrolled antiretroviral experienced, HIV-infected adults currently receiving a regimen of TDF/FTC+ATV/r for ≥6 months with no history of virologic failure and whose HIV-1 RNA had been ≤ 75 copies/mL on 2 consecutive measurements including screening. Patients were randomized 1:2 to continue current treatment or simplify to ABC/3TC+ATV. Methods: The primary endpoint was the proportion of patients with HIV-RNA<50 copies/mL at Week 24 by the Time to Loss of Virologic Response (TLOVR) algorithm. Secondary endpoints included alternative measures of efficacy, adverse events (AEs), and fasting lipids. Exploratory endpoints included inflammatory, coagulation, bone, and renal biomarkers. Results: After 24 weeks, ABC/3TC+ATV (n = 199) was non-inferior to TDF/FTC+ATV/r (n = 97) by both the primary analysis (87% in both groups) and all secondary efficacy analyses. Rates of grade 2-4 AEs were similar between the two groups (40% vs 37%, respectively), but an excess of hyperbilirubinemia made the rate of grade 3-4 laboratory abnormalities higher in the TDF/FTC+ATV/r group (30%) compared with the ABC/3TC+ATV group (13%). Lipid levels were stable except for HDL cholesterol, which increased significantly in the ABC/3TC+ATV group. Bone and renal biomarkers improved significantly between baseline and Week 24 in patients taking ABC/3TC+ATV, and the difference between groups was significant at Week 24. No significant changes occurred in any inflammatory or coagulation biomarker within or between treatment groups. Conclusions: After 24 weeks, simplification to ABC/3TC+ATV from TDF/FTC+ATV/r maintained viral suppression was welltolerated, and led to improvements in bone and renal biomarkers and HDL cholesterol. Trial Registration: ClinicalTrials.gov NCT01102972 GlaxoSmithKline Clinical Study Register 113734
Date of publication
Keyword
DOI
Identifier
Resource type
  • Article
Rights statement
  • In Copyright
License
  • Attribution 3.0 United States
Journal title
  • PLoS ONE
Journal volume
  • 9
Journal issue
  • 5
Language
  • English
ISSN
  • 1932-6203
Publisher
  • Public Library of Science

Relations

Parents:

This work has no parents.

In Collection:

Items

Thumbnail Title Date Uploaded Visibility Actions
file details journal.pone.0096187.PDF 2020-08-14 Public Download